These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34778040)

  • 101. Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy.
    Bobrowski D; Kumar R; Wu PE; Lapointe-Shaw L
    Clin Case Rep; 2021 Nov; 9(11):e05057. PubMed ID: 34786197
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
    Jalaludin MY; Deeb A; Zeitler P; Garcia R; Newfield RS; Samoilova Y; Rosario CA; Shehadeh N; Saha CK; Zhang Y; Zilli M; Scherer LW; Lam RLH; Golm GT; Engel SS; Kaufman KD; Shankar RR
    Pediatr Diabetes; 2022 Mar; 23(2):183-193. PubMed ID: 34779103
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
    Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
    JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
    Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Fixed Drug Eruption Secondary to Four Anti-diabetic Medications: An Unusual Case of Polysensitivity.
    Al Masri D; Fleifel M; Hirbli K
    Cureus; 2021 Oct; 13(10):e18599. PubMed ID: 34786218
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves.
    Katsurada K; Nandi SS; Sharma NM; Patel KP
    Circ Heart Fail; 2021 Dec; 14(12):e008365. PubMed ID: 34789005
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure.
    Vaduganathan M; Greene SJ; Zhang S; Solomon N; Chiswell K; Devore AD; Butler J; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Mcdermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Fonarow GC
    J Card Fail; 2022 Apr; 28(4):554-563. PubMed ID: 34785402
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Egyptian Atherosclerosis and Vascular Biology Association Consensus on the Use of Sodium Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction.
    Elserafy AS; Reda A; Farag E; Mostafa T; Farag N; Elbahry A; Sanad O; Bendary A; Elkersh A; Attia I; Selim M; Khamis H; Issak ER
    Clin Drug Investig; 2021 Dec; 41(12):1027-1036. PubMed ID: 34780022
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
    Butler J; Filippatos G; Jamal Siddiqi T; Brueckmann M; Böhm M; Chopra VK; Pedro Ferreira J; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Shah SJ; Senni M; Vedin O; Verma S; Peil B; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Jan; 145(3):184-193. PubMed ID: 34779658
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials.
    Chaudhuri A; Ghanim H; Arora P
    Diabetes Obes Metab; 2022 Mar; 24(3):365-376. PubMed ID: 34779091
    [TBL] [Abstract][Full Text] [Related]  

  • 111. A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
    Shankar RR; Zeitler P; Deeb A; Jalaludin MY; Garcia R; Newfield RS; Samoilova Y; Rosario CA; Shehadeh N; Saha CK; Zhang Y; Zilli M; Scherer LW; Lam RLH; Golm GT; Engel SS; Kaufman KD
    Pediatr Diabetes; 2022 Mar; 23(2):173-182. PubMed ID: 34779087
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region.
    Liao CT; Yang CT; Kuo FH; Lee MC; Chang WT; Tang HJ; Hua YM; Chang HY; Chen ZC; Strong C; Ou HT; Toh HS
    Front Cardiovasc Med; 2021; 8():750381. PubMed ID: 34778407
    [No Abstract]   [Full Text] [Related]  

  • 113. SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness.
    Cavallari I; Maddaloni E; Nusca A; Tuccinardi D; Buzzetti R; Pozzilli P; Grigioni F
    Am J Cardiovasc Drugs; 2022 May; 22(3):263-270. PubMed ID: 34786655
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models.
    Li H; Zhang Y; Wang S; Yue Y; Liu Q; Huang S; Peng H; Zhang Y; Zeng W; Wu Z
    Front Pharmacol; 2021; 12():756226. PubMed ID: 34790128
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts.
    Marfella R; D'Onofrio N; Trotta MC; Sardu C; Scisciola L; Amarelli C; Balestrieri ML; Grimaldi V; Mansueto G; Esposito S; D'Amico M; Golino P; Signoriello G; De Feo M; Maiello C; Napoli C; Paolisso G
    Metabolism; 2022 Feb; 127():154936. PubMed ID: 34801581
    [TBL] [Abstract][Full Text] [Related]  

  • 116. EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction.
    Wagdy K; Nagy S
    Glob Cardiol Sci Pract; 2021 Oct; 2021(3):e202117. PubMed ID: 34805375
    [No Abstract]   [Full Text] [Related]  

  • 117. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
    Shubrook JH; Neumiller JJ; Wright E
    Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.
    Kim HM; Hwang IC; Choi W; Yoon YE; Cho GY
    Sci Rep; 2021 Nov; 11(1):22342. PubMed ID: 34785723
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.
    Shaffner J; Chen B; Malhotra DK; Dworkin LD; Gong R
    Front Endocrinol (Lausanne); 2021; 12():749010. PubMed ID: 34790170
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Cardiovascular benefit of SGLT2 inhibitors.
    Mohebi R; Januzzi JL
    Crit Rev Clin Lab Sci; 2022 May; 59(3):142-155. PubMed ID: 34784839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.